Fulcrum Therapeutics (FULC) Q4 2025 earnings summary

Executive summary

• 12-week data from the 20-mg cohort of the phase I-B PIONEER trial in sickle cell disease showed rapid and robust induction of fetal hemoglobin (HbF), with a mean absolute increase of 12.2% (from 7.1% to 19.3%).

• Over half of patients achieved HbF levels ≥20%, a threshold linked to meaningful clinical protection.

• Marked improvements were observed in hemolysis markers, anemia, and reduction in vaso-occlusive crises (VOCs), with 7 of 12 patients reporting no VOCs during treatment.

• Pociredir was generally well-tolerated at 20 mg, with no treatment-related serious adverse events or discontinuations.

• Ended 2025 with $352.3 million in cash, cash equivalents, and marketable securities, providing a cash runway into 2029.

Financial highlights

• Cash, cash equivalents, and marketable securities increased to $352.3 million as of December 31, 2025, up from $241.0 million at year-end 2024.

• Completed a $164.2 million public offering in December 2025 to support ongoing development.

• Research and development expenses for 2025 were $56.1 million, down from $63.4 million in 2024, mainly due to program discontinuations and cost sharing.

• General and administrative expenses for 2025 were $28.7 million, down from $36.4 million in 2024.

• Net loss for 2025 was $74.9 million, compared to $9.7 million in 2024.

Outlook and guidance

• Plans to update on next trial design in Q2, pending FDA feedback, with a potential registration-enabling trial to start in the second half of 2026.

• Engagement with the European Medicines Agency is planned for mid-2026.

• Cash runway is expected to fund operations into 2029 based on current plans.

• An open-label extension study is being activated to assess long-term safety and durability.